Drugs that contain Aripiprazole Lauroxil

1. List of Aristada drug patents

ARISTADA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(9 years from now)

US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

49

United States

15

Japan

10

Australia

9

New Zealand

9

European Union

8

Canada

6

China

6

Israel

4

Russia

4

Spain

2

Portugal

2

Brazil

2

Croatia

2

Argentina

2

Mexico

2

Hong Kong

2

Lithuania

2

Cyprus

2

Hungary

2

Slovenia

2

Poland

2

RS

2

Denmark

1

San Marino

1

IB

1

Morocco

1

Taiwan, Province of China

1

Saudi Arabia

2. List of Aristada Initio Kit drug patents

ARISTADA INITIO KIT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

31

United States

11

Japan

8

European Union

6

Canada

4

Spain

4

China

4

Australia

3

Portugal

3

Croatia

3

Lithuania

3

Hungary

3

Slovenia

3

Poland

3

RS

3

Denmark

2

Russia

2

New Zealand

2

Argentina

2

Cyprus

2

Israel

1

Turkey

1

Brazil

1

Mexico

1

Taiwan, Province of China

1

Hong Kong

1

Saudi Arabia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in